Spinal fluid chemo combo shows promise for advanced lung cancer

NCT ID NCT05805631

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of pemetrexed (given into the spinal fluid) and a tyrosine kinase inhibitor for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) after the drug osimertinib stops working. The study aims to see if this approach can control the disease and improve survival. About 23 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pemetrexed (given into the spinal fluid) plus a tyrosine kinase inhibitor
What this could lead to
If it works, this could offer a new treatment option for people with lung cancer that has spread to the lining of the brain and spinal cord after standard therapy fails.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply to everyone. The treatment involves injecting chemotherapy into the spinal fluid, which carries risks like infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Chest Medicine, Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.